BioxyTran, Inc. filed a Form 8-K on November 5, 2026, disclosing that on November 4, 2026, the company announced it had secured an Attested Free Sale Certification for its product A-SUQAR, described as opening a path to the UAE and Gulf markets.
Comfort Systems USA, Inc. filed a Form 8-K on November 5, 2026, disclosing that its Board of Directors approved an amendment to its stock repurchase program, authorizing the acquisition of up to 994,606 additional shares to restore the available balance to 1,000,000 shares.
Microsoft Corporation filed a Form 8-K on November 5, 2026, disclosing that board director Emma N. Walmsley notified the company on November 4, 2026, that she would not stand for re-election at the company's 2026 annual shareholder meeting.
Lincoln National Corporation filed a Form 8-K with the U.S. Securities and Exchange Commission on November 5, 2026, disclosing its financial results for the quarter ended September 30, 2026, alongside supplemental materials made available in connection with its third quarter 2026 earnings conference call.
Prestige Consumer Healthcare Inc. filed a Form 8-K with the SEC on November 5, 2026, announcing financial results for the fiscal quarter and six months ended September 30, 2026, and disclosing the start of an investor presentation under Regulation FD.
3D Systems Corporation filed a Form 8-K on November 5, 2026, disclosing that on November 4, 2026, it entered into Exchange Agreements with all holders of its outstanding 5.875% Convertible Senior Secured Notes due 2030 to exchange those notes for cash, common stock, and …
Vistra Corp. filed a Form 8-K on November 5, 2026, disclosing the October 30, 2026 completion of its acquisition of Q-Generation, LLC from Q-Generation Holdings, LLC, involving approximately $2.2 billion in cash and 5,000,000 shares of Vistra common stock.
Mentari Therapeutics, Inc., formerly InMed Pharmaceuticals Inc., filed a Form 8-K on November 5, 2026, disclosing a corporate name change, a 1-for-10 common share consolidation, and the creation of a new Series A Non-Voting Preferred Share class, all effective November 4, 2026, in connection …
DataMEDS AI, Inc. filed a Form 8-K on November 5, 2026, disclosing that it terminated, effective November 3, 2026, a Second Amended and Restated Letter of Intent with six counterparties including EOS Technology Holdings, Inc. and Scilex Holding Company.
Cognition Therapeutics, Inc. filed a Form 8-K on November 5, 2026, disclosing that it received a Nasdaq deficiency letter on November 3, 2026, for failing to maintain the minimum $1.00 per share closing bid price, and separately announcing financial results for the quarter ended …